Liposome Drug Delivery Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.50 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Liposome Drug Delivery Market Analysis
The liposome drug delivery market is expected to register a CAGR of 8.5% during the forecast period of the study.
COVID-19 impacted the liposome drug delivery market as various R&D activities involving liposome drug delivery were postponed around the world by the respective government of the countries. However, the importance of liposomes in drug delivery was realized soon and intensive research started on the liposome drug delivery system for the treatment of COVID-19 which propelled the market growth in the later phase of the pandemic. For instance, according to the research study published in the Asian Journal of Pharmaceutical Sciences in November 2021, the researchers developed lyophilized remdesivir liposomes (Rdv-lips), which could be reconstituted as a liposomal aerosol for pulmonary delivery to improve the in vivo behavior of existing remdesivir cyclodextrin conclusion compound (Rdv-cyc) injections and liposome encapsulation endowed remdesivir with much higher solubility and better biocompatibility, and thus, increased the efficacy of the drug. The market is growing in the current scenario because the companies are still engaged in the development of therapeutics against COVID-19, in which liposome-based drugs or vaccines can play a vital role.
The major factor driving the growth of the liposome drug delivery market is the increasing demand for effective and efficient therapeutics since liposome-based drug delivery method offers certain advantages over other delivery systems. For instance, according to the research study published in Molecules Journal in February 2022, liposomes have better properties than standard drug delivery methods, such as site-targeting, prolonged or controlled release, drug protection from degradation and clearance, higher therapeutic effects, and lesser toxic side effects.
Also, the application of liposomes to assist drug delivery has shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving the biodistribution of compounds to target sites in vivo. This enables the effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes are an appealing delivery system due to their adaptable physicochemical and biophysical properties, which allow for easy manipulation to address various delivery concerns. Hence, they are the preferred choice of drug manufacturers.
Furthermore, with the increasing prevalence of chronic diseases such as cancer, diabetes, fungal infections, and others around the world, the demand for effective therapeutics is increasing, which is expected to fuel the growth of the liposome drug delivery market. For instance, according to the December 2021 update of the International Diabetes Federation (IDF), about 537 million adults of age 20 to 79 years were living with diabetes around the world in 2021, and this number is estimated to reach 643 million by 2030 and 783 million by 2045. The projected rise in the number of diabetes cases globally is expected to boost demand for liposomal diabetes therapeutics to increase its efficacy and reduce the toxicity and hence, drive growth of the studied market.
In addition, the increasing advancement in the liposomal drug delivery method with the new investments in the area along with product launches, acquisitions, and collaborations by the market players is further expected to boost the growth of the liposome drug delivery market. For instance, in October 2021, Evonik Health Care, an integrated contract development and manufacturing organization (CDMO) that offers excipients, formulation technologies, and clinical and commercial manufacturing, launched a new version of its established LIPEX liposome extruder. LIPEX Flow meets the market need for more efficient, next-generation high-pressure extruders to produce drug products requiring conventional liposomal drug delivery, including drugs for oncology, vaccines, and other applications.
Therefore, owing to the above-mentioned factors, the studied market is expected to experience significant growth during the study period. However, stringent regulatory policies and adverse effects associated with drug delivery are expected to restrain the growth of the liposome drug delivery market during the forecast period of the study.
Liposome Drug Delivery Market Trends
Cancer Therapeutics are Expected to Account for the Largest Market Share During the Forecast Period
Cancer therapeutics are expected to hold a significant share due to the high prevalence of cancer globally and the rising demand for advanced therapeutics. For instance, as per the Australian Institute of Health and Welfare (AIHW) 2022 report, a total of 162,000 new cancer cases were diagnosed in Australia in 2022. Also, as per Canadian Medical Association Journal, May 2022 report, 28,600 new breast cancer were diagnosed in Canada in 2022. The high burden of cancer globally is expected to propel the segment's growth during the forecast period.
Furthermore, according to the research study published in Nanoscale Research Letters in May 2021, liposomes' high flexibility and capacity for chemical modification by conjugating diverse polymers, ligands, and molecules are a big positive for liposomes in cancer therapeutics, and it increases their pharmacological merits and boosts anticancer treatment effectiveness. Further, as per the same source, liposomes can improve the sensitivity, specificity, and persistence of anti-malignant cell agents in the body, and thus, liposomes are used widely in cancer therapeutics. Therefore, with the rising research studies and advantages offered by liposomes in cancer therapeutics, its demand is expected to witness growth during the forecast period.
Therefore, due to the high prevalence of cancer, the advantages of liposome drug delivery methods over others, the cancer therapeutics segment is expected to hold a major share in the liposome drug delivery market during the forecast period of the study.
North America is Expected to Hold a Significant Share in the Market over the Forecast Period
North America is expected to dominate the liposome drug delivery market due to the high prevalence of chronic diseases in the region, the increasing geriatric population, and the launches of innovative products by the market players.
The high burden of chronic diseases in the region is expected to propel the demand for therapeutics, which is expected to drive growth in the North American region. For instance, according to the CDC's 2022 update, the percentage of coronary heart disease for adults aged 18 and over in the United States increased to 4.9% in 2021 as compared to 4.6% in the previous years. Additionally, according to the American Cancer Society statistics of 2023, around 1.9 million new cancer cases are predicted to be diagnosed in the United States in 2023. Liposomes improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Therefore, the demand for liposome drug delivery is rising for CVD and cancer therapeutics.
Furthermore, the rising government funding for research of various diseases in the United States also plays a crucial role in the growth of the market in the region. For instance, the allocated budget for the National Cancer Institute (United States) for FY 2022 was USD 6.9 billion, which was USD 353 million net increase over FY 2021. Thus, the high spending for R&D in the United States is expected to significantly propel the market in the region during the forecast period.
Liposome Drug Delivery Industry Overview
The liposome drug delivery market is highly competitive with the presence of several players in the market who are engaged in the development of drugs. Also, the companies in the area are continuously enhancing their product offering through new launches, collaborations, partnerships, mergers, and acquisitions which are further expected to increase the competition in the studied market. Some of the key players in the liposome drug delivery market are Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Johnson and Johnson, and Ipsen Biopharmaceuticals, Inc., among others.
Liposome Drug Delivery Market Leaders
-
Gilead Sciences, Inc.
-
Pacira BioSciences, Inc.
-
Luye Pharma Group
-
Johnson and Johnson
-
Ipsen Biopharmaceuticals, Inc.
*Disclaimer: Major Players sorted in no particular order
Liposome Drug Delivery Market News
- In June 2022, Endo International plc's subsidiary Endo Ventures Limited (EVL) entered into an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in phase 3 development for the treatment of osteoarthritis knee pain.
- In January 2022, Sun Pharma Advanced Research Company was manufacturing a liposome-encapsulated formulation of the taxane compound paclitaxel (a tubulin inhibitor) for the treatment of breast cancer.
Liposome Drug Delivery Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Cronic Diseases Like Cancer
- 4.2.2 Advantages Associated With The Liposome Drug Delivery System
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Policies and Adverse Effects Associated with the Drug Delivery
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By Product
- 5.1.1 Liposomal Paclitaxel
- 5.1.2 Liposomal Doxorubicin
- 5.1.3 Liposomal Amphotericin B
- 5.1.4 Others
-
5.2 By Technique
- 5.2.1 Stealth Liposome Technology
- 5.2.2 Non-PEGylated Liposome Technology
- 5.2.3 DepoFoam Liposome Technology
-
5.3 By Indication
- 5.3.1 Fungal Infections/Diseases
- 5.3.2 Cancer Therapeutics
- 5.3.3 Pain Management
- 5.3.4 Viral Vaccines
- 5.3.5 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Gilead Sciences, Inc.
- 6.1.2 Pacira BioSciences, Inc.
- 6.1.3 Spectrum Pharmaceuticals, Inc.
- 6.1.4 Takeda Pharmaceutical Company Limited
- 6.1.5 Luye Pharma Group
- 6.1.6 Johnson and Johnson
- 6.1.7 Ipsen Pharma
- 6.1.8 Celsion Corporation
- 6.1.9 Teva Pharmaceutical Industries Ltd.
- 6.1.10 Novartis AG
- 6.1.11 Sun Pharmaceutical
- 6.1.12 Acrotech Biopharma, Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLiposome Drug Delivery Industry Segmentation
As per the scope of the report, liposomes are lipid-based bilayer vesicles that can encapsulate, deliver, and release low-soluble drugs and small molecules to a specific target site in the body. They've been shown to help stabilize therapeutic compounds, overcome barriers to cellular and tissue uptake, and improve the biodistribution of compounds to target sites in vivo. Liposomes are a desirable delivery technology because of their adaptable physicochemical and biophysical features, which allow for easy customization to meet a variety of delivery needs. The liposome drug delivery market is segmented by product (liposomal paclitaxel, liposomal Doxorubicin, liposomal Amphotericin B, and others), technique (stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology), indication (fungal infections/diseases, cancer therapeutics, pain management, viral vaccines, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | Liposomal Paclitaxel | |
| Liposomal Doxorubicin | ||
| Liposomal Amphotericin B | ||
| Others | ||
| By Technique | Stealth Liposome Technology | |
| Non-PEGylated Liposome Technology | ||
| DepoFoam Liposome Technology | ||
| By Indication | Fungal Infections/Diseases | |
| Cancer Therapeutics | ||
| Pain Management | ||
| Viral Vaccines | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Liposome Drug Delivery Market Research FAQs
What is the current Global Liposome Drug Delivery Market size?
The Global Liposome Drug Delivery Market is projected to register a CAGR of 8.5% during the forecast period (2024-2029)
Who are the key players in Global Liposome Drug Delivery Market?
Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Johnson and Johnson and Ipsen Biopharmaceuticals, Inc. are the major companies operating in the Global Liposome Drug Delivery Market.
Which is the fastest growing region in Global Liposome Drug Delivery Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Liposome Drug Delivery Market?
In 2024, the North America accounts for the largest market share in Global Liposome Drug Delivery Market.
What years does this Global Liposome Drug Delivery Market cover?
The report covers the Global Liposome Drug Delivery Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Liposome Drug Delivery Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Liposome Drug Delivery Industry Report
Statistics for the 2024 Liposome Drug Delivery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Liposome Drug Delivery analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
